This issue is important because concerns about microheterogeneity have a long history. In the 1940s and early 1950s, proteins (and nucleic acids) were considered to be colloids that were unlikely to display the atomic and molecular precision of "real" molecules. This view, of course, began to dissipate with the Watson-Crick structure of DNA, the demonstration that at least some small proteins could be refolded into equilibrium conformations, and the finding that macromolecules could be crystallized and discrete structures obtained by X-ray diffraction. These developments appeared, at the time, to relegate earlier concerns about microheterogeneity into the dustbin of scientific history. On the other hand, modern studies of protein and RNA folding and assembly suggest that there may be multiple pathways of folding and that individual proteins-and certainly individual macromolecular assemblies-could be trapped into metastable states with long-term stability. Learning more about such distributions of metastable states and their rates of rearrangement is of great intrinsic interest because this may tell us more about folding and assembly processes in vivo and in vitro and also about how far these processes are driven toward homogeneity by chaperone complexes. In addition, such functional heterogeneity, if it exists, may provide further insight into regulatory events controlled by signal-transduction networks because these regulatory processes could work somewhat differently on "outliers" within conformational distributions of macromolecular assemblies.
The receptor tyrosine kinase (RTK) family of cell-surface receptors includes the epidermal growth factor receptor (EGFR/ErbB1/HER1) and its relatives ErbB2/HER2, ErbB3/ HER3, and ErbB4/HER4. Receptors of the EGFR subgroup are essential for embryonic development and adult tissue homeostasis in both vertebrates and invertebrates. Enhanced signaling from these receptors, due to mutation or overexpression, contributes to several types of human cancer (reviewed in Yarden and Sliwkowski, 2001) . Like their RTK brethren, members of the EGFR subgroup feature an extracellular region (ectodomain) that binds polypeptide ligands (EGF, transforming growth factor-α, neuregulins, and several others), a single-pass transmembrane helix, and a cytoplasmic domain containing intrinsic tyrosine kinase activity (reviewed in Schlessinger, 2002) .
RTK activation represents a signal transduction event in which an extracellular cue (such as a growth factor) is converted to a cellular response (for example, cell division) through a series of intracellular steps. The activation process for RTKs is simple yet complex. It A study by Zhang et al. (2006) in this issue of Cell provides compelling evidence that the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) is activated by the formation of an asymmetric dimer, with one kinase domain in the EGF-mediated dimer activating the other through an allosteric mechanism.
appears simple because the fundamental mechanism is ligandinduced receptor clustering. But it is complex due to the different ligand-receptor stoichiometries and the various mechanisms by which kinase activity is repressed in nonactivated receptors and stimulated in activated receptors (reviewed in Schlessinger, 2000; Hubbard, 2004) . In this issue of Cell, Zhang et al. (2006) provide evidence for an allosteric mechanism of kinase activation for the EGFR.
Several years ago, a wealth of structural data emerged on the ectodomain of EGFR and its relatives. These data revealed the molecular mechanisms by which the ectodomain is converted from a dimerization-inhibited state to a dimerization-competent state after binding of ligand (reviewed in Burgess et al., 2003) . In structural terms, binding of EGF to its receptor facilitates formation of a symmetric EGF-EGFR complex (with 2:2 stoichiometry) on the extracellular side of the plasma membrane ( Figure 1A ). But what transpires on the cytoplasmic side of the plasma membrane? For most ligand-RTK complexes, ligand-mediated receptor dimerization is thought to position the two cytoplasmic tyrosine kinase domains for efficient trans-phosphorylation of tyrosine residues in the kinase activation loop, the juxtamembrane region (linking the transmembrane helix to the kinase domain), and elsewhere in the cytoplasmic domain. These phosphorylation events, particularly in the activation loop and juxtamembrane region, stabilize the catalytically competent state of the kinase (reviewed in Huse and Kuriyan, 2002; Hubbard, 2004) . Phosphorylation sites also serve to recruit downstream signaling proteins containing Src homology-2 (SH2) or phosphotyrosine binding (PTB) domains. In contrast with most RTKs, all of the EGFR sites of tyrosine autophosphorylation, which recruit a host of signaling proteins, reside in a long flexible segment that is C-terminal to the kinase domain.
Despite containing a conserved tyrosine residue in the activation loop (Tyr845), phosphorylation of this tyrosine is not required for activation of the EGFR kinase. If not tyrosine phosphorylation, what then is the basis for activation of the EGFR kinase? Here is where the study by Zhang et al. (2006) weighs in. A previous crystal structure of the soluble EGFR kinase domain (which is monomeric up to relatively high protein concentrations) showed the kinase to be in an active state (Stamos et al., 2002) , with the principal regulatory elements-the activation loop in the C-terminal kinase lobe (C-lobe) and α helix C in the N-terminal kinase lobe (N-lobe)-properly positioned for catalysis. This was consistent with the observation that phosphorylation of the activation loop was not necessary for kinase activity, but it raised the question of why the EGFR kinase is not constitutively active. Zhang et al. (2006) went hunting for a crystal packing interaction that might resolve this conundrum. They asked whether there may exist in the crystal structure an interaction between two kinase domains that could explain why the crystallized kinase is in an active state, and, if so, whether this interaction might take place within the confines of a ligand-stabilized EGFR dimer.
The authors drew on their knowledge of the structural intricacies of kinase activation in the nonreceptor tyrosine kinase Src and the serine/ threonine kinase cyclin-dependent kinase-2 (CDK2). They identified an intriguing crystal packing interacfigure 1. formation of an Active eGfeGfR Dimer (A) On the extracellular side of the plasma membrane (shown approximately to scale), the EGF:EGFR complex (2:2 stoichiometry) is 2-fold symmetric (the 2-fold axis is vertical). Depicted are the two receptors in the complex (cyan and purple) with the four subdomains (I-IV) of the EGFR ectodomain and their bound EGF ligands (orange; E). The transmembrane helices are shown as cylinders, and linker segments including the juxtamembrane regions (extracellular and cytoplasmic) and C-terminal tail as lines. On the cytoplasmic side of the plasma membrane, the two tyrosine kinase domains (with N-and C-lobes) form an asymmetric dimer, with the C-lobe (C) of one kinase domain (purple) interacting with the N-lobe (N) of the other kinase domain (cyan). This interaction activates the second kinase domain (cyan). Tyrosine phosphorylation sites in the C-terminal tail of the cytoplasmic domain are depicted as red spheres. The composite structure is derived from PDB codes 1VO and 1NQL (ectodomain dimer) and from PDB code 1M14 (cytoplasmic domain dimer).
(B) The mechanism of EGFR kinase activation: shown are the N-lobes and C-lobes of the EGFR kinase domains, the β sheet in the N-lobe containing Lys721 (orange; K), α helix C in the N-lobe containing Glu738 (green; E), and the activation loop in the C-lobe containing Leu834 (gray; L). The C-lobe of one kinase domain (purple) activates the second kinase domain (cyan) by interacting with α helix C, which facilitates formation of the Lys721-Glu738 salt bridge (red dashed line) and proper positioning for catalysis of the activation loop. In the absence of such an interaction (kinase colored purple), the activation loop is stabilized in a Src/CDK-like inactive state in which a short α helix in the activation loop (containing Leu834) and α helix C are stabilized in an inactive configuration. The two kinase domains are presumed to reverse roles in a dynamic fashion. tion in the EGFR kinase structure in which the C-lobe of one EGFR kinase molecule makes contact with the N-lobe of a symmetry-related molecule. Notably, the symmetry element that relates these two kinase molecules is a 3-fold screw axis, which means that this dimer is asymmetric rather than symmetric (related by a 2-fold axis). In this asymmetric interaction, the C-lobe of one kinase "pushes" α helix C (N-lobe) of the other kinase toward the active site such that a critical lysine-glutamate (Lys721-Glu738) salt bridge can be made ( Figure 1B) . Although the molecular details differ, this interaction is highly reminiscent of the activation of CDK2 by binding of cyclinA (Jeffrey et al., 1995) .
Structural insights gained from the preexisting EGFR kinase structures (Stamos et al., 2002; Wood et al., 2004) , as well as from newly determined structures of their own, led Zhang et al. (2006) to propose that, following ligand-mediated dimerization of the EGFR, the two EGFR kinase domains form a cyclin/ CDK-like asymmetric dimer in which one kinase activates the other allosterically. From elegant biochemical studies of mutated forms of EGFR with an altered dimer interface, Zhang et al. (2006) provide strong support for this proposal. In addition, there is evolutionary data to support this mechanism. A sequence alignment of the four kinase domains of the EGFR subgroup shows that the C-lobe residues in the dimer interface are conserved, that is, all four members are potential activators. In contrast, the relevant sequence in the N-lobe of the ErbB3 kinase, the one member of the subgroup that cannot be activated (due to substitutions of key catalytic residues), is not conserved. This mechanism nicely explains how the catalytically inactive ErbB3 can still be an "active" participant in a heterodimeric complex with one of the other members of the subgroup (Yarden and Sliwkowski, 2001 ).
To get a picture of the basal (low activity) state of the EGFR kinase, Zhang et al. (2006) introduced a mutation (V924R) in the C-lobe of the EGFR kinase domain to prevent formation of the asymmetric (activated) dimer. As predicted, the mutant kinase domain crystallizes in a different lattice, and the configuration of the important regulatory elements (activation loop, α helix C) now resembles the inactive state of Src/ CDK ( Figure 1B) . A crystal structure of the EGFR kinase with an inhibitor bound (Wood et al., 2004) provided the first indication of this autoinhibited state, but it was unclear whether the inhibitor induced this state. The structure of the V924R mutant thus supplies another important piece to the EGFR activation puzzle: in the monomeric state, the kinase domain of the EGFR is autoinhibited because the activation loop and α helix C, if not actually locked down in a Src/CDK-like inactive configuration, can readily "sample" such an inactive configuration.
This structure of the monomeric, inactive state of the EGFR kinase also sheds light on an important clinical finding. Recent studies of nonsmall-cell lung cancer have shown that the small-molecule inhibitor gefitinib is highly efficacious for a subpopulation of patients who harbor particular mutations in the EGFR kinase domain (reviewed in Minna et al., 2004) . These mutations are clustered in the kinase activation loop, the nucleotide binding loop (Nlobe), and the linker between the β sheet and α helix C. Although there has been some controversy as to whether these are kinase-activating mutations, the structure of the basal-state EGFR kinase (Zhang et al., 2006) , along with accompanying biochemical data, indicates that the mutated residues (such as Leu834) are indeed important for maintaining basal-level catalytic activity ( Figure  1B) . Moreover, because they destabilize the inactive state of the kinase, these mutations render the kinase domain vulnerable to gefitinib, which binds selectively to the active state. Although the wild-type EGFR (and other classes of mutants) becomes susceptible to gefitinib upon ligandinduced dimerization, these particular kinase mutants are constitutive targets of the drug.
Several mechanistic issues pertaining to EGFR activation remain outstanding, such as the extent to which EGFR exists as an inactive dimer on the cell surface, the structural nature of such a dimer, and the roles played by the transmembrane helix and C-terminal tail of the EGFR. Nevertheless, the Zhang et al. (2006) study fills some gaping holes in our knowledge of the regulatory mechanisms controlling this important subgroup of RTKs. It also reminds us that, although there is a natural inclination for us to seek out symmetry, biology has its own criteria, and in some cases asymmetry will do just fine.
